• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [18422 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2001     Basque Office for Health Technology Assessment (OSTEBA) [Cost-effectiveness analysis of treatments of sleep apnea syndrome in the Basque Country]
2009     Norwegian Knowledge Centre for the Health Services (NOKC) [Cost-effectiveness of childhood vaccination against rotavirus in Norway]
2014     National Evidence-based Healthcare Collaborating Agency (NECA) [Cost-effectiveness of conventional cytology and HPV DNA testing for cervical cancer screening in South Korea]
2013     National Evidence-based Healthcare Collaborating Agency (NECA) [Cost-effectiveness of human papillomavirus vaccination in South Korea]
2014     Basque Office for Health Technology Assessment (OSTEBA) [Cost-effectiveness of percutaneous aortic valve replacement using prosthetic valve versus the standard surgical treatment]
2010     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Cost-utility analysis of pharmacological treatments for the prevention of bone fractures in osteoporotic post-menopausal Spanish women]
2011     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Cost-utility analysis of the introduction of universal infant rotavirus vaccination in Spain]
2010     Belgian Health Care Knowledge Centre (KCE) [Cost-utility of vaccination against chickenpox in children and against herpes zoster in elderly in Belgium]
2013     National Evidence-based Healthcare Collaborating Agency (NECA) [Costing methods in healthcare]
2013     Belgian Health Care Knowledge Centre (KCE) [Coupling of the permanent sample with the hospital data: feasibility and data representativeness study]
2011     Norwegian Knowledge Centre for the Health Services (NOKC) [Criteria for assessment of the effect of preventive interventions]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Criteria for indication and surgical treatment in Parkinson´s disease and epilepsy]
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Crizotinib - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2016     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Crizotinib (lung cancer) - Benefit assessment according to §35a Social Code Book V]
2016     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Crizotinib (new therapeutic indication) - benefit assessment according to §35a Social Code Book V]
2016     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Crizotinib (new therapeutic indication) – benefit assessment according to §35a SGB V]
2016     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Crizotinib: addendum to commission A15-59]
2006     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Cross-sectorial cooperation between general practice and hospital - shared care elucidated using anticoagulant therapy as an example - a health technology assessment]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Cryoablation for the treatment of persistent or symptomatic paroxysmal atrial fibrillation]
2014     Basque Office for Health Technology Assessment (OSTEBA) [Cryoablation in atrial fibrillation with Arctic Front catheter]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Cryopreservation of parathyroid glands for deferred autologous transplant in the management of hyperparathyroidism with surgical indication]
2010     Committee for New Health Technology Assessment (CNHTA) [Cryostripping]
2012     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [CT coronary angiography versus conventional invasive coronary angiography in CHD]
2009     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) [Curative treatment for esophageal cancer: systematic review of neoadjuvant therapy and chemoradiotherapy alone: summary]
2014     National Evidence-based Healthcare Collaborating Agency (NECA) [Current status and outcomes analysis of radiosurgery for spinal tumours]
2013     Institut national d'excellence en sante et en services sociaux (INESSS) [Current strategies for optimizing the relevance of laboratory test prescription: a review of Canadian and international experiences]
2009     Committee for New Health Technology Assessment (CNHTA) [CYBB gene mutation analysis(sequencing)]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [CYD tetravalent dengue vaccine]
2020     National Committee for Technology Incorporation (CONITEC) [Cytoreductive surgery (peritonectomy) with hyperthermic intraperitoneal chemotherapy (HIPEC)]
2013     The Regional Health Technology Assessment Centre (HTA-centrum) [Cytoreductive surgery and intraperitoneal chemotherapy (HIPEC or EPIC) in patients with colorectal adenocarcinoma and peritoneal carcinomatosis.]
2020     National Committee for Technology Incorporation (CONITEC) [Cytoreductive surgery with hyperthermic chemotherapy in patients with malignant peritoneal mesothelioma]
2013     The Regional Health Technology Assessment Centre (HTA-centrum) [Cytoreductive surgery with intraperitoneal chemotherapy for pseudomyxoma peritonei]
2011     Institute for Clinical Effectiveness and Health Policy (IECS) [Dabigatran and rivaroxaban as thrombophylaxis after major orthopedic surgery]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Dabigatran etexilate for the prevention of stroke or systemic embolism in patients with non-vascular atrial fibrillation]
2011     Institute for Clinical Effectiveness and Health Policy (IECS) [Dabigatran for the prevention of ischemic stroke in patients with acute or chronic atrial fibrillation]
2011     The Swedish Council on Health Technology Assessment (SBU) [Dabigatran to prevent stroke in patients with atrial fibrillation]
2016     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dabrafenib (new therapeutic indication): benefit assessment according to §35a Social Code Book V]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dabrafenib (non-small cell lung cancer) - benefit assessment according to §35a Social Code Book V]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Dabrafenib plus trametinib for advanced melanoma]
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dabrafenib: benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daclatasvir - benefit assessment according to section 35a Social Code Book V (dossier assessment)]
2015     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daclatasvir (addendum to Commission A14-31)]
2007     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Daily hemodialysis vs conventional hemodialysis: systematic review of clinical results and economic analysis]
2007     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Daily hemodialysis vs conventional hemodialysis: systematic review of clinical results and economic analysis]
2011     Institute for Clinical Effectiveness and Health Policy (IECS) [Dalfampridine (ampyra) in multiple sclerosis patients]
2002     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Danish stroke treatment]
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dapagliflozin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dapagliflozin/metformin: benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2016     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab - assessment according to §35a (para. 1, sentence 10) Social Code Book V]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (multiple myeloma) – benefit assessment according to §35a Social Code Book V]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Daratumumab for relapsed or refractory multiple myeloma]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Darolutamide (prostate cancer) - Addendum to Commission A20-43]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Darunavir-cobicistat-emtricitabine-tenofovir alafenamide (HIV infection) - benefit assessment according to §35a Social Code Book V]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Darunavir-cobicistat-emtricitabine-tenofovir alafenamide (HIV infection) - benefit assessment according to §35a Social Code Book V]
2015     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dasabuvir: benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dasabuvir/ombitasvir/paritaprevir/ritonavir (addendum to Commissions A15-03 and A15-04)]
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Day surgery: a systematic overview]
2012     Haute Autorite de sante (HAS) [Day surgery: an overview]
2011     Committee for New Health Technology Assessment (CNHTA) [Debridement using hydrosurgery system]
2010     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Decentralized cooperation for development in health and environment: Assessment of barriers and opportunities]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Decision aid for biomarker tests in breast cancer - addendum to commission D14-01]
2013     National Evidence-based Healthcare Collaborating Agency (NECA) [Decision Making and Safety Issues in Health Services and Technologies]
2008     Andalusian Health Technology Assessment Area (AETSA) [Decision making tool for patients with non valvular atrial fibrillation]
2010     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Decision-analytic modeling to evaluate the long-term effectiveness and cost-effectiveness of HPV-DNA testing in primary cervical cancer screening in Germany]
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Decitabin - Assessment according to § 35a (para. 1, sentence 10) Social Code Book V (dossier assessment)]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Deep anterior lamellar keratoplasty in keratoconus]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Deep brain stimulation for Parkinson's disease]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Deep brain stimulation in patients with treatment-resistant depressive disorder, obsessive compulsive disorder and Tourette syndrome]
2010     Andalusian Health Technology Assessment Area (AETSA) [Deep brain stimulation in the treatment of depressive and obsessive-complusive disorders]
2005     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Deep brain stimulation using electrodes in the treatment of Parkinson's Disease]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Deferred parathyroid autograft with cryopreserved tissue for the surgical management of hyperparathyroidism]
2009     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Defibrillators in public places]
2011     Committee for New Health Technology Assessment (CNHTA) [Deletion of 18q choromosome in colorectal cancer (LOH, loss of heterozygosity)]
2007     Andalusian Health Technology Assessment Area (AETSA) [Denaturing high performance liquid chromatography (DHPLC). Use and utility in massive genotyping]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Denosumab for the treatment of solid tumor bone metástasis]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Denosumab versus bisphosphonates for the treatment of osteoporosis in post-menopausal women]
2010     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Dental indications for standardised procedures of instrumental functional analysis under consideration of health economic aspects]
2013     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Descemet Stripping Automated Endothelial Keratoplasty (DSAEK) for corneal endothelial dysfunction]
2005     Basque Office for Health Technology Assessment (OSTEBA) [Description of the elaboration of a clinical practice guidelines for asthma in the autonomous community of the Basque country by means of a mixed method of adaptation-development-actualization]
2012     Institut national d'excellence en sante et en services sociaux (INESSS) [Description of the use of Proton Pump Inhibitors (PPIs) in adults covered by the public prescription drug insurance plan]
2021     Center for Drug Evaluation (CDE) [Descriptive study and comparative effectiveness of listed medications for osteoporosis on new osteoporotic fracture event in osteoporosis patients by using National Health Insurance claim database]
2010     Basque Office for Health Technology Assessment (OSTEBA) [Design and implementation plan of telemedicine in specific clinical areas: telemonitoring and teledermatology. Assessment of initial results and costs]
2016     Basque Office for Health Technology Assessment (OSTEBA) [Design and validation of a screening tool for evaluating the health impact of regional policies]
2013     Basque Office for Health Technology Assessment (OSTEBA) [Design of an interaction protocol between Primary Care and Hospitals to improve early detection and monitoring of patients with multiple sclerosis]
2011     Health Intervention and Technology Assessment Program (HITAP) [Designing a decision frame for making health resource allocation decisions: a case study in Thailand]
2015     Institut national d'excellence en sante et en services sociaux (INESSS) [Detection and diagnosis of Alzheimer's disease and other neurocognitive disorders]
2014     Haute Autorite de sante (HAS) [Detection of enterovirus genome in cerebrospinal fluid by gene amplification in meningitis patients]
2010     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Detection of high risk human papillomavirus E6 and E7 oncogenes for cervical cancer screening]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Detection of sperm DNA fragmentation (TUNEL, SCSA, SCD, COMET) and use of annexin columns (MACS) in assisted reproduction treatments]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Determination of antigen expression levels of uPA and PAI-1 in primary breast cancer with intermediate recurrence risk after R0 primary surgery]
2008     Basque Office for Health Technology Assessment (OSTEBA) [Development and evaluation of tools designed in order to ensure patient safety for possible incorporation into the management of healthcare processes]
2010     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Development and Validation of Methods for Quality Assessment of Health Technologies Assessment reports: Evaluation Manual for Ethics in Health Technology Assessment]
2012     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Development and validation of methods for quality assessment of health technologies assessment reports. Evaluation of the quality of qualitative studies]
2008     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Development and validation of methods for quality assessment of health technologies assessment reports]
2010     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Development and validation of methods for quality assessment of health technologies assessments reports : assessment of ethical issues in health technologies assessment]
2015     Institut national d'excellence en sante et en services sociaux (INESSS) [Development framework for social services practice guidelines]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Development of a basic set of expert consensus-based quality indicators for the care delivered to stroke patients]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Development of a model for predicting emergency hospital admission and readmission in Catalonia]
2014     National Evidence-based Healthcare Collaborating Agency (NECA) [Development of a preference-based instrument: Asian Comparative Study]
2009     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Development of a shared knowledge system for network assessment of technological innovation in medicine]